When Meghan MacDonald visited her primary care provider in the fall of 2022 to get a lump in her breast examined, they confirmed her suspicion that it was just an inflamed cyst. Relieved, MacDonald began a course of antibiotics, but when the lump didn’t go away, her doctor ordered a mammogram, and when the results ... Read more The post Metastatic Breast Cancer Survivor Proves Her Endurance at NYC Marathon  appeared first on Dana-Farber Cancer Institute ..read more

To help reduce the risk of cancer, the American Cancer Society recommends at least 150 minutes a week of exercise or activity — a 30 minute walk each weekday, for instance — plus some strength training twice a week for good physical health.   But researchers at Dana-Farber and other cancer centers are exploring the possibility ... Read more The post An Rx for Exercise: Can Exercise Be a Part of Cancer Treatment?  appeared first on Dana-Farber Cancer Institute ..read more

For a while, Stephanie Dobson attributed her gastrointestinal issues to her pregnancy. It was her second, a girl born in May 2023, a baby sister to her son. But when the symptoms persisted for the 34-year-old mother, she raised the issue with her primary care provider.   She was encouraged to see a gastroenterologist. On an ... Read more The post Young Mother with Lynch Syndrome Doing Well on Immunotherapy  appeared first on Dana-Farber Cancer Institute ..read more

Bispecific antibody therapies are a type of immunotherapy for patients with B-cell non-Hodgkin lymphoma. These therapies provide a valuable new option for patients.  There are many standard therapies that are monoclonal antibodies. These therapies treat cancer by binding to a marker on cancer cells and rallying the immune system to destroy them.  Bispecific antibodies are ... Read more The post Bispecific Antibody Therapy for Lymphoma: What You Need to Know    appeared first on Dana-Farber Cancer Institute ..read more

BCL2 inhibitors are drugs that prompt cancer cells to die by altering the interactions among key proteins within the cells. They were clinically developed, in large part, by researchers at Dana-Farber and have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukemia ... Read more The post BCL2 Inhibitors: What’s the Latest Research? appeared first on Dana-Farber Cancer Institute ..read more

Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma, diagnosed in more than 18,000 people in the U.S. every year. It is a fast-growing lymphoma that can arise in the lymph nodes or, more rarely, in organs such as the spleen, liver, and others.  As its name indicates, DLBCL involves the ... Read more The post Diffuse Large B-Cell Lymphoma: What to Know  appeared first on Dana-Farber Cancer Institute ..read more

Throughout the 20 years Robert Jenkins has been living with follicular lymphoma, he has been through many different treatments — from traditional chemotherapy protocols to innovative approaches like CAR T-cell therapy and bispecific antibodies. His lengthy survivorship has allowed Jenkins to benefit from new advances as they’ve emerged, and along with his wife, Lorna, one ... Read more The post A Patient-Doctor Bond Forged in Fighting Follicular Lymphoma   appeared first on Dana-Farber Cancer Institute ..read more

Dana-Farber researchers have found that a transcription factor called SOX17 gives colon cancer a safe space to develop.  The post One Genetic Switch Undermines Immune System’s Efforts to Thwart Colon Cancer  appeared first on Dana-Farber Cancer Institute ..read more

Lung cancer is on the rise in young people, particularly those who are assigned female at birth (AFAB). The post Guiding Lung Cancer Treatment During Pregnancy  appeared first on Dana-Farber Cancer Institute ..read more

If you have received a positive result from a GRAIL Galleri test, which is a multi-cancer early detection (MCED) blood test, you need further testing to determine if you have cancer.   If you have a positive GRAIL test, that means the test has found a signal that is associated with cancer and requires investigation. Other ... Read more The post My GRAIL Test was Positive. Now What?  appeared first on Dana-Farber Cancer Institute ..read more